PRNewsWire
03 Sept 2026, 20:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics faces allegations that it resubmitted a Biologics License Application for Deramiocel using statistical analysis changes not agreed upon by the FDA. — Lack of FDA alignment on primary analysis plans significantly increases the risk of a Complete Response Letter (CRL) or rejection of the drug.
-0.80A securities fraud class action lawsuit has been filed alleging Capricor made materially misleading statements regarding the prospects of Deramiocel for Duchenne muscular dystrophy. — Litigation creates financial liability and signals potential governance failures, which generally weighs on stock valuation.
-0.50The lawsuit claims there is a substantial risk that the FDA may conclude Deramiocel's clinical results do not provide substantial evidence of effectiveness. — Direct challenges to the efficacy data of a lead pipeline candidate are high-signal negative catalysts for biotech firms.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is facing a securities fraud class action lawsuit alleging misleading statements regarding FDA communications and clinical data for its lead product.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
5h ago
